Skip to main content
Figure 1 | Cancer Cell International

Figure 1

From: Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter

Figure 1

Endogenous hTERT activity and cell killing effect of Ad/gTRAIL: (A) Endogenous hTERT mRNA level in meningioma and glioma cells. The hTERT mRNA level in primary cultured meningioma cells and glioma cell lines was determined by real time quantitative PCR as described the Methods. The levels of β-actin was used as endogenous controls. (B) In vitro cell-killing effect of Ad/TRAIL on various brain tumor cells. (B-1) Meningioma cells (B-2) Glioma cells. Cell viability was determined by XTT assay. Cells treated with PBS were used as a control, and their viability was set at 1. Values are mean ± SD for two quadruplicate assays PBS (mock control), Ad/CMV-GFP (vector control), and M43, M2, M66, M6 and NG-1 SW1088, U251, U87, Ad/gTRAIL., Cells were treated with MOI of 1000 VPs/ cell at 7 consecutive days. Cell viabiligy of M6, U251, and U87 cells treated with Ad/gTRAIL was significantly different (p< 0.001) from that of Ad/CMV-GFP and PBS treated cells.

Back to article page